Business
Universal Ibogaine Announces Private Placement Financing and the Results of the Annual Meeting of Shareholders
(TheNewswire) Calgary, AB – TheNewswire - April 22, 2024 – Universal ...
About this update from Universal Ibogaine Inc
[{"type":"text","content":"Universal Ibogaine Announces Private Placement Financing and the Results of the Annual Meeting of Shareholders\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, AB –\n \n \n TheNewswire -\n \n \n April 22, 2024 – Universal Ibogaine Inc.\n(\n \n \n TSXV:IBO\n \n \n ) (“\n \n \n UI\n \n \n ” or the “\n \n \n Company\n \n \n ”), a life sciences company with a\nmission to research and deliver medicalized ibogaine-centered\naddiction care, advises that it intends to undertake a non-brokered\nprivate placement offering of up to 23,333,333 common shares at a\nprice of $0.015 per share, for proceeds of up to $350,000 (the\n“\n \n \n Offering\n \n \n ”).\n \n \n \n \n Completion of the Offering is subject to approval by\nthe TSX Venture Exchange (the “\n \n \n TSXV\n \n \n ”).  All shares issued under the\nOffering will be subject to a four\n \n \n ‐\n \n \n month hold period as required by the\nrules of the TSXV and Canadian Securities Laws, as well as any\nrequired hold periods under US Securities Laws for US resident\npurchasers.\n \n \n \n \n Proceeds from the Offering are intended to be used in\nthe Company’s planned ibogaine based clinical trial application\nprocess with Health Canada, and for general working capital purposes.\n \n \n \n \n UI currently has a total of 291,070,449 common shares\nissued and outstanding.\n \n \n \n \n Annual Meeting of Shareholders\n \n \n \n \n The Company also advises the results of its annual\nmeeting of shareholders (the “\n \n \n Meeting\n \n \n ”) held on April 18, 2024, at which\nthe Company’s shareholders approved the following matters:\n \n \n \n \n \n \n Election of the Board of Directors (the\n \n \n Board\n \n \n ”) - the\nCompany’s three incumbent members of the Board were re-elected and\nnew Director nominee Ken Cranwill was elected, with each Board member\nto hold office until the next annual meeting of shareholders or until\ntheir successors are duly elected or appointed.\n \n \n \n \n \n \n Appointment of Auditors - MNP LLP were appointed as the\nauditors of the Company for the next fiscal year at a remuneration to\nbe determined by the Board of Directors.\n ...